# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹1,179 Cr** Q4 FY26 (+12% YoY) · **₹1,937 Cr** FY26 (+7% YoY) * **PAT:** **₹86 Cr** Q4 FY26 (+17% YoY / +84% QoQ) * **Leverage & Efficiency:** **0.99x** Net Debt-to-EBITDA · **59 Days** Net Working Capital * **Dividends:** **₹2.5/share** Final Dividend · **₹5/share** Total FY26 Dividend ## B. Revenue Growth * **Multi-Year Highs:** Achieved highest quarterly top-line and EBITDA performance in 14 quarters, underpinned by robust double-digit volume expansion. * **Volume Recovery:** Annual growth was primarily catalyzed by a recovery in Specialty Chemicals and strong fundamental demand. * **Innovator Pipeline:** Management is focused on executing a **₹6 Cr** yearly trade revenue stream with innovators following early-quarter delays. ## C. Margins & Profitability * **Earnings Momentum:** Quarterly run-rate EBITDA has surged significantly compared to two years prior, demonstrating resilience despite volatile market conditions. * **Pricing Strategy:** To protect margins, the company is actively balancing price fluctuations in building blocks against **Beta-picoline**, which is currently at multi-year price highs. ## D. Balance Sheet & Capital Allocation * **Deleveraging Success:** Net debt was reduced by **11%** during 2026, resulting in a sub-1.0x leverage ratio that provides a platform for accelerated growth in Q1 FY27. * **Asset Conversion:** Capital work-in-progress (CWIP) has moderated to approximately **₹150 Cr**, signaling the transition of projects into operational assets. * **Shareholder Returns:** Total dividend payout for the fiscal year reached **₹79.8 Cr**, representing a 500% payout on face value. --- # 2. Operating Segments ## A. Key Figures * **Specialty Chemicals Revenue:** **₹516 Cr** Q4 FY26 (+6% YoY / +13% QoQ) * **Nutrition Revenue:** **₹230 Cr** Q4 FY26 (+21% YoY / +15% QoQ) · **₹790 Cr** FY26 * **Nutrition EBITDA:** **₹32 Cr** Q4 FY26 (+42% QoQ) (14% Margin) · **₹100 Cr** FY26 * **Chemical Intermediates Revenue:** **₹433 Cr** Q4 FY26 (+15% YoY / +10% QoQ) ## B. Specialty Chemicals * **Record Performance & Margin Stability:** Achieved highest-ever quarterly revenue while maintaining remarkably consistent margins for six consecutive quarters. * **Strategic Mix Shift:** Business profile has pivoted toward high-value specialty and nutrition products, which now represent the vast majority of total EBITDA. * **Segment Drivers:** Growth anchored by strong Pharmaceutical volumes and robust Agrochemical export visibility, supported by successful price hikes. ## C. Nutrition & Care * **Volume & Price Momentum:** Robust double-digit growth driven by niacinamide demand in feed/cosmetics and strong choline exports to Europe. * **Inorganic Expansion:** Full-year performance bolstered by the **Remidex Pharma** acquisition, facilitating entry into Human Nutrition and Premix Solutions. * **Personal Care Pipeline:** Secured **two contract wins** with several additional opportunities in advanced-stage discussions, signaling a strengthening market position. ## D. Chemical Intermediates * **Operational Efficiency:** Revenue growth supported by effective cost pass-through and domestic volume strength in the paracetamol and agrochemical sectors. * **Inventory Advantage:** Strategic raw material locking during the **February** market escalation provided a tailwind that is expected to persist into **Q1**. ## E. CDMO Business * **High-Growth Engine:** Maintaining a consistent annual growth rate of **30% to 40%** (currently consolidated under Specialty Chemicals) with expanding opportunities in semiconductors and pharma. * **Execution Excellence:** Successfully delivered two agrochemical molecules "first time right" in record time, enhancing industry reputation with global majors. * **Aggressive Scaling:** Management targets scaling the Pharma CDMO vertical to **3x-4x** its current size, underpinned by a rapid influx of new molecule announcements. --- # 3. Manufacturing & Capacity ## A. Key Figures * **Pyridine & Picoline Capacity:** **50,000 tons** Total Global Capacity (>90% Utilization) * **B3 Plant Utilization:** **40% to 50%** Projected peak volume capacity for current FY ## B. Plant Commissioning & Operational Excellence * **CDMO Infrastructure Expansion:** The Bharuch CDMO plant was commissioned in a record **14 months**, successfully passing a **USFDA audit** and receiving a **WEF Lighthouse Award**. * **Strategic Roadmap:** Construction of the Gajraula MPP plant is progressing as a core pillar of the company’s long-term CDMO growth strategy. * **Sustainability & Efficiency:** Operational performance is underscored by significant lean savings and a **97th percentile** S&P Global CSA ranking. ## C. Utilization Levels & Product Scaling * **Market Leadership:** Maintained dominant global position in Pyridine and Picoline, supported by consistently high utilization rates. * **B3 Product Ramp-up:** PC-grade niacinamide has achieved rapid scaling, reaching half of its peak volume within one year, significantly outpacing the Niacin segment. ## D. Project Timelines * **Gajraula MPP Completion:** The major ongoing investment project remains on track for completion this year, with production slated to commence in **Quarter 4**. --- # 4. Product & Pipeline ## A. Key Figures * **Total Pipeline Value:** **₹3,500 Cr** potential (100+ opportunities) · **₹1,100 Cr** peak potential (10+ advanced-stage) * **Pipeline Mix:** **70%** Non-Pyridine · **25%–30%** Pyridine-based * **Pharma CDMO Growth:** **3x** pipeline expansion vs. 2 years ago * **Revenue Ramp-up:** **20%–25%** (Year 1) · **50%–60%** (Year 2) · **>80%** (Year 3) ## B. Molecule Development * **Aggressive Funnel Expansion:** Added **8 new molecules** this quarter to a robust pipeline designed to mitigate development mortality rates through sheer volume. * **Pharma CDMO Pivot:** Strategic focus on Phase II and Phase III intermediates to embed in innovator supply chains, targeting commercial scale within **4 to 6 years**. * **High-Value Conversion:** Management expects near-term P&L impact from scaling commercialized molecules and the imminent announcement of a **reasonably sized** late-stage project. * **Semiconductor Entry:** Engaging in nearly a **dozen active projects**; while current revenue is minimal, it represents a long-term growth journey requiring calibrated customer validation. ## C. Portfolio Mix * **Chemistry Diversification:** Successfully shifted away from Pyridine dependence by leveraging a portfolio of **30-plus chemistries** to drive non-Pyridine opportunities. ## D. CDMO Contracts * **Major Contract Execution:** Shipments for the large-scale CDMO contract began in **March**, with ongoing discussions to finalize volume scenarios for the fiscal year. * **Agrochemical Momentum:** Serving a major contract with clear Q1 visibility while preparing to scale a smaller agri contract in **H2 FY27**. * **Early-Mover Advantage:** Strategy focuses on entering the value chain early to capture exponential scale-up alongside innovators upon molecule success. ## E. Customer Engagement * **Innovator Traction:** Record engagement levels with **5 to 6 top agrochemical innovators**; approximately **40%** of the total pipeline now originates from innovator companies. * **Pharma Credibility:** Active promotion of CDMO capabilities has significantly increased engagements with Tier 1 players and global innovators. --- # 5. Strategic Initiatives ## A. Key Figures * **Pinnacle Growth Targets:** **3x** Revenue and **4x** EBITDA by **FY30** * **Targeted EBITDA Growth:** **20% to 25%** per year (Organic) ## B. Pinnacle Journey * **Strategic Roadmap:** The initiative has optimized cost structures and portfolio mix, with **FY27** identified as a pivotal year for accelerated growth driven by core drivers and Acetyls recovery. * **CDMO Scaling:** Currently in the early stages of establishing CDMO credibility, the company expects to begin scaling operations this year with potential for **nonlinear growth** as the pipeline matures. * **Market Momentum:** Achieved significant market share gains in European Acetyls and sustained shipment momentum across Pyridine and CDMO segments. ## C. M&A Activity & Vertical Restructuring * **Strategic Acquisitions:** Completed the acquisition of **Remidex Pharma** to forward-integrate the Human Nutrition vertical, leveraging existing Vitamin B3 and B4 production. * **Organizational Realignment:** Transitioned to a vertical-specific structure (Pharma, Agro, Semiconductor, etc.) supported by senior leadership hires to provide integrated customer solutions. * **Operational Milestones:** Successfully commenced dispatches from the newly commissioned **Agro CDMO facility**, marking a key step in specialty chemicals expansion. ## D. Market Expansion * **Geographic Traction:** Strong revenue momentum in Japan, Korea, and Southeast Asia, particularly within Nutrition and Personal Care segments. * **Semiconductor & Japan Focus:** Business development in Japan has yielded a "healthy" pipeline; active discussions are underway with international semiconductor firms for Indian partnerships. * **European Market Share:** Anticipating robust volume growth in Europe following the successful qualification of Acetyl products with nearly all major regional customers. --- # 6. Risks & External Factors ## A. Key Figures * **Pyridine Pricing:** **$2.5–$4.0/unit** historical range · **"Rock bottom"** current levels * **Chinese Pyridine Capacity:** **250,000–300,000 tons** total · **30%–40%** utilization rates * **Contract Value:** **$300 million** (signed Oct 2024) ## B. Agrochemical & Competitive Landscape * **Contractual Safeguards:** Despite delayed volume visibility due to market volatility, "make-whole" clauses ensure bottom-line projections remain insulated from shortfalls. * **Chinese Cost Pressures:** Massive pricing pressure and slow market movement from China are weighing on industry progress, though the company maintains a superior cost structure. * **Strategic Positioning:** The company is positioned as the primary "China Plus One" alternative, leveraging global supply chain diversification trends to capture international market share. ## C. Currency & Supply Chain Resilience * **Natural Hedge Strategy:** The massive new contract is protected against FX volatility as dollar-denominated import costs for raw materials and equipment roughly offset export revenues. * **Operational Continuity:** Zero production loss or force majeure declarations recorded during Middle East instability, demonstrating high supply chain reliability. * **Pricing Power:** Resilient demand and effective pass-through mechanisms have allowed for firming prices despite rising crude-linked input costs. ## D. Market Disruptions & Intermediates * **Favorable Pricing Outlook:** Supply for Chemical Intermediates is tightening due to European plant closures and mechanical failures at competitors, supporting a positive pricing environment. * **Inventory Management:** Potential margin compression from falling **acetic acid** prices is expected to be neutralized by **Q1/Q2** due to disciplined, cautious purchasing during peak price cycles. --- # 7. Guidance & Outlook ## A. Key Figures * Annual Capex: ₹500 Cr planned for next year ## B. Growth Targets * **Sequential Recovery:** Management anticipates a turnaround in revenue and EBITDA starting **Q1 FY27**, fueled by Specialty Chemicals, Nutrition, and an Acetyls recovery. * **CDMO Acceleration:** Revenue momentum in the CDMO segment is expected to pick up in **FY27**, underpinned by major contract wins and new market entry. * **Strategic Pillars:** Long-term expansion remains anchored to Fine Chemicals (Pyridine/Diketene), the Nutrition portfolio, and high-value cosmetic grade molecules. ## C. Capex & Margin Sustainability * **Investment Discipline:** Capital deployment is focused on supporting growth following the recent **March capitalization** of the CDMO plant. * **Margin Drivers:** Specialty Chemical profitability is supported by CDMO scaling and internal cost optimization, offsetting pressures from trading and derivatives. ## D. Long-term Projections * **Contractual Backing:** A significant **$300 million contract** acts as the primary catalyst for the current fiscal year's growth projections. * **Agrochemical Resilience:** Despite global volatility, the company expects to match or exceed prior-year volumes, with significant long-term scaling potential.